Imatinib Mesylate in Treating Patients With Myelofibrosis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
myelofibrosis. Imatinib mesylate may stop the growth of myelofibrosis by blocking certain
enzymes necessary for cell growth.